Close Menu

NEW YORK – Evotec said today that it has acquired certain assets from Ncardia related to the use of induced pluripotent stem cells for drug discovery.

The assets include intellectual property relevant to iPSC-based phenotypic drug discovery and an existing undisclosed product business around iPSC-derived cells. Evotec said it is also taking on 17 stem cell biology experts operating out of laboratories at the BioCampus Cologne in Germany.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The editorial board of the Pittsburgh Post-Gazette says other lawmakers should take Florida's approach and provide additional protections against genetic discrimination.

The Hill reports 17 states and the District of Columbia are suing over a new policy that would strip international students of their visas if they only attend classes online.

Centers for Disease Control and Prevention employees call on the agency to label racism a public health crisis and examine its own policies, NPR reports.

In PNAS this week: genetic evidence for Inca resettlement, analysis of spermatogonial stem cell transcriptomes, and more.